Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PsychoGenics, which specializes in phenotypic drug discovery, has achieved a milestone in its drug discovery and development collaboration with Roche.
Subscribe to our email newsletter
The two companies entered into a drug discovery and development collaboration on May 2008 with an aim to discover new treatments for neuropsychiatric disorders.
PsychoGenics evaluated a library of Roche compounds and discovered a new drug candidate which is believed to have novel mode of action.
Roche will exercise its option to develop this drug candidate, resulting in a milestone payment to PsychoGenics.
PsychoGenics’ makes use of in vivo behavioral expertise and recent developments in robotics, computer vision, and bioinformatics to assess drug candidates for potential utility across the spectrum of Central Nervous System (CNS) disease indications.